Neoplasms Malignant clinical trials

Explore recruiting neoplasms malignant clinical trials.

Recruiting neoplasms malignant studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neoplasms Malignant trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Next Generation StaR TREC - Save the rectum by watchful waiting after (chemo)Radiotherapy or Total mesorectal excision for early REctal Cancer?

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mHSPC) and in men with heavily pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC) with or without prior 177Lu-labelled PSMA-targeted radioligand therapy

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuxiMAb or BevacizumaB

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

First-in-Human Study of RLY-2608 in Advanced Breast Cancer and Other Solid Tumors.

Spain, France, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Neoplasms Malignant trials by city

Neoplasms Malignant in Toronto Neoplasms Malignant in Vancouver Neoplasms Malignant in Montreal Neoplasms Malignant in Calgary Neoplasms Malignant in Edmonton Neoplasms Malignant in Ottawa Neoplasms Malignant in Winnipeg Neoplasms Malignant in Quebec City Neoplasms Malignant in Hamilton Neoplasms Malignant in Kitchener Neoplasms Malignant in London Neoplasms Malignant in Halifax Neoplasms Malignant in New York Neoplasms Malignant in Los Angeles Neoplasms Malignant in Chicago Neoplasms Malignant in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease